Dashboard
Manage Tickers

CDTX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

janus-henderson-avidity-biosciences-bridgebio-pharma-and-other-big-stocks-moving-higher-on-monday
Janus Henderson, Avidity Biosciences, Brid...
10/27/2025 14:21:30

cidara-therapeutics-presents-data-on--cd388-candidate-at-european-scientific-working-group-on-influenza-in-spain
Cidara Therapeutics Presents Data On CD38...
10/23/2025 12:03:47

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

hc-wainwright--co-reiterates-buy-on-cidara-therapeutics-maintains-150-price-target
HC Wainwright & Co. Reiterates Buy on Cida...
10/21/2025 16:28:56

HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $150 price ta...

cidara-therapeutics-releases-new-phase-2b-clinical-data-from-its-navigate-study-showing-its-influenza-preventative-candidate-cd388-demonstrated-up-to-761-efficacy-against-influenza-a-and-b-in-healthy-unvaccinated-adults
Cidara Therapeutics Releases New Phase 2b ...
10/21/2025 12:10:33

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-...

morgan-stanley-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-190
Morgan Stanley Initiates Coverage On Cidar...
10/16/2025 13:07:28

Morgan Stanley analyst Maxwell Skor initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and ann...

cidara-therapeutics-analyst-says-lead-influenza-candidate-is-strategically-attractive
Cidara Therapeutics Analyst Says Lead Infl...
10/10/2025 18:11:11

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's...

cidara-therapeutics-surges-ahead-of-eswi-2025-presentation-and-jp-morgan-coverage
Cidara Therapeutics Surges Ahead of ESWI 2...
10/10/2025 14:55:59

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement ...

cidara-therapeutics-to-present-cd388-navigate-phase-2b-influenza-data-at-eswi-2025-showcasing-cloudbreak-dfc-platform-in-late-breaking-abstract
Cidara Therapeutics To Present CD388 NAVIG...
10/10/2025 12:14:57

jp-morgan-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-200
JP Morgan Initiates Coverage On Cidara The...
10/10/2025 11:32:13

JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and announces...

wbb-securities-maintains-strong-buy-on-cidara-therapeutics-raises-price-target-to-199
WBB Securities Maintains Strong Buy on Cid...
10/09/2025 18:33:40

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-150
HC Wainwright & Co. Maintains Buy on Cidar...
10/09/2025 14:50:58

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target ...

fda-grants-breakthrough-therapy-designation-for-cidaras-cd388-for-preventing-influenza-a--b-in-high-risk-populations
FDA Grants Breakthrough Therapy Designatio...
10/09/2025 12:02:37

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

cidara-shares-are-trading-higher-friday-whats-going-on
Cidara Shares Are Trading Higher Friday: W...
10/03/2025 16:53:54

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic i...

jmp-securities-maintains-market-outperform-on-cidara-therapeutics-raises-price-target-to-173
JMP Securities Maintains Market Outperform...
10/03/2025 12:07:49

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the pric...

cidara-secures-up-to-339m-barda-award-to-advance-cd388-pandemic-influenza-therapeutic-and-us-manufacturing
Cidara Secures Up To $339M BARDA Award To ...
10/02/2025 20:06:30

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Cidar...
09/26/2025 10:44:24

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target...

cidara-therapeutics-announces-first-participants-dosed-in-phase-3-trial-to-evaluate-safety-and-efficacy-of-cd388-non-vaccine-preventative-of-seasonal-influenza-in-high-risk-populations
Cidara Therapeutics Announces First Partic...
09/25/2025 20:03:26

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere- Participants will include adults ove...

guggenheim-maintains-buy-on-cidara-therapeutics-raises-price-target-to-167
Guggenheim Maintains Buy on Cidara Therape...
09/25/2025 12:56:16

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target from...

needham-maintains-buy-on-cidara-therapeutics-raises-price-target-to-100
Needham Maintains Buy on Cidara Therapeuti...
09/24/2025 16:10:22

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $74 ...

wbb-securities-reiterates-strong-buy-on-cidara-therapeutics-maintains-123-price-target
WBB Securities Reiterates Strong Buy on Ci...
09/24/2025 11:22:28

WBB Securities analyst Steve Brozak reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and maintains $123 price ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION